
Junji Matsui, PhD, senior director, Eisai, discusses a preclinical study of eribulin (Halaven) demonstrating anti-proliferative activity in select soft tissue sarcoma cell lines.

Your AI-Trained Oncology Knowledge Connection!


Published: May 5th 2016 | Updated: